JACC Heart Failure Editor's Update, January 2019
JANUARY 2018 MINI-FOCUS ISSUE: DRUG THERAPY
The hospital setting offers an excellent opportunity to study the effects of continuing or changing medical therapies for HFrEF patients. While guideline-directed medical therapy (GDMT) for HFrEF patients in an outpatient setting has been studied extensively, gaps in the provision of these therapies remain. Aditi Bhagat, Javed Butler, and colleagues analyze the impact of initiating new medical therapies or making other changes to the medical management of hospitalized HFrEF patients, and provide a conceptual framework for inpatient decision making to optimize GDMT for HFrEF patients. Click below to learn more:
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization
Aditi A. Bhagat, Stephen J. Greene, et al
Does a history of atrial fibrillation (AF) and/or atrial flutter (AFL) predict the course of in-hospital decongestion in acute heart failure patients? Ravi Patel et al pooled HFrEF and HFpEF patients from 3 randomized trials and looked at the association between a history of AF and/or AFL and in-hospital changes in various metrics of congestion. This study raises interesting questions about the hemodynamic effects of AF and AFL, and the possible efficacy of therapies to promote decongestion and improve clinical outcomes in this patient population. Click below to read more:
History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure
Ravi B. Patel, Muthiah Vaduganathan, et al
Research on dyskalemia has generally not extended across the full spectrum of heart failure patients. Dyskalemia is known to be associated with morbidity and mortality in HFrEF patients, but its incidence and impact in patients with preserved and mid-range ejection fraction is less well studied. Gianluigi Savarese and colleagues looked at the clinical data of patients from the Swedish-HF Registry and the Stockholm CREAtinine Measurements (SCREAM) project and explored predictors of dyskalemia and outcomes. Read below:
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction
Gianluigi Savarese, Hong Xu, et al
MEET ASSOCIATE EDITOR: Peter Pang
Peter S. Pang, MD, MS, FAHA, FACC, FACEP, is the Vice Chair of Strategic Innovation and an Associate Professor of Emergency Medicine & Medicine (Cardiology) at the Indiana University School of Medicine. He recently became a Hoosier after spending 10 years at Northwestern University in Chicago as Associate Chief and Associate Director of Experimental Therapeutics in the Center for Cardiovascular Innovation. Dr. Pang went to medical school at the University of Texas Health Science Center at San Antonio and then completed residency and chief residency at the Brigham and Women’s / Massachusetts General Hospital combined program in Emergency Medicine. His primary research area is acute heart failure with funding from NIH, AHA, and the AHRQ. He has published extensively in this area.
3 Things People May Not Know about Me:
- My parents had immigrated from Korea only a few years before I was born. When they became aware that growing up with a name like Peter Pang would make me a magnet for punishment, they unofficially changed my first name to Joseph. My parents, siblings, and friends through college call me Joe. From med school forward, I went back to Peter since that was my official name and the name that was on my name tags. It got old correcting people all the time and, by then, it was no big deal.
- Prior to med school, I had been accepted to Theological Seminary. The plan was a Master of Divinity and “Reverend Joe…”
- You might think an ER doc wouldn’t be jumpy, but I am. My kids love hiding and scaring me. I literally scream like it’s the end…plus, I loathe spiders.
NEW JOURNAL FEATURE
I am also excited to announce a new feature for Original Research papers. Due to the popularity of our Central Illustrations in State-of-the-Art papers, JACC: Heart Failure will now include a Central Illustration for all New Research Papers. The Central Illustration summarizes the main point of the manuscript or a major section of the manuscript. One of the Figures of the manuscript may be designated. We hope you enjoy this additional special feature of the journal! For more information, see below:
All Original Research Papers and State-of-the-Art Reviews must develop 1 Central Illustration, which summarizes the main point of the manuscript or at least a major section of the manuscript. If one of the Figures already provided in your manuscript is a key figure summarizing the major findings, you may designate that figure as the Central Illustration in the legend. The figure may incorporate multiple panels including key figures or graphics, or short text lists summarizing key points or variables. The purpose of these illustrations is to provide a snapshot of your paper in a single visual, conceptual manner. This illustration must be accompanied by a legend (title and caption). The Central Illustration must be an original image and, for copyright reasons, cannot be adapted or reprinted from another source.